Medical marijuana has stepped onto the global stage.
In what appears to be a first for marijuana and a major pharmaceutical company, a Novartis subsidiary and a Canadian producer of medical cannabis products have agreed to market them around the world.
Tilray Canada announced the agreement on Tuesday with Sandoz, a unit of Swiss-based Novartis that manufactures generic and biosimilar drugs. Under the deal, whose financial terms were not disclosed, Tilray and Sandoz will work together to supply and distribute non-smokable medical cannabis products. The companies will also co-brand and develop other products together.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect